We are live on ! Find out more
VEA

Virtus ETF Advisers Portfolio holdings

AUM $215M
1-Year Est. Return 53.68%
This Fund
S&P 500
This Quarter Est. Return
+12.8%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$237M
AUM Growth
-$4.18M
Cap. Flow
-$18.3M
Cap. Flow %
-7.71%
Top 10 Hldgs %
7.93%
Holding
416
New
61
Increased
247
Reduced
47
Closed
61

Sector Composition

Rank Sector Weight
1 Healthcare 30.46%
2 Real Estate 18.03%
3 Energy 13.68%
4 Materials 11.34%
5 Utilities 10.99%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
HTGC icon
176
Hercules Capital
HTGC
$3.01B
$415K 0.18%
25,879
-2,324
-8% -$36K
AMTI
177
DELISTED
Applied Molecular Transport Inc. Common Stock
AMTI
$415K 0.18%
9,424
+161
+2% +$7.83K
BCSF icon
178
Bain Capital Specialty
BCSF
$826M
$411K 0.17%
27,815
+613
+2% +$8.45K
GBDC icon
179
Golub Capital BDC
GBDC
$3.37B
$407K 0.17%
27,848
+2,230
+9% +$32.8K
MGNX icon
180
MacroGenics
MGNX
$241M
$403K 0.17%
12,648
+229
+2% +$5.56K
ALEC icon
181
Alector
ALEC
$168M
$401K 0.17%
19,917
+354
+2% +$6.35K
MCI
182
Barings Corporate Investors
MCI
$343M
$401K 0.17%
28,762
+6,442
+29% +$87.1K
GLAD icon
183
Gladstone Capital
GLAD
$436M
$400K 0.17%
20,183
-1,104
-5% -$21.2K
HRZN icon
184
Horizon Technology Finance
HRZN
$294M
$398K 0.17%
27,690
+10,565
+62% +$147K
KRYS icon
185
Krystal Biotech
KRYS
$10.4B
$397K 0.17%
5,151
+99
+2% +$7.2K
GAIN icon
186
Gladstone Investment Corp
GAIN
$651M
$390K 0.16%
31,850
-5,991
-16% -$68.9K
ADAP
187
DELISTED
Adaptimmune Therapeutics
ADAP
$389K 0.16%
73,237
+1,283
+2% +$7.34K
TSLX icon
188
Sixth Street Specialty
TSLX
$1.68B
$388K 0.16%
18,469
+937
+5% +$20.1K
DTIL icon
189
Precision BioSciences
DTIL
$182M
$387K 0.16%
1,246
+21
+2% +$7.35K
KRTX
190
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$383K 0.16%
3,186
+64
+2% +$7.25K
NBP
191
NovaBridge Biosciences American Depositary Shares
NBP
$202M
$381K 0.16%
7,860
+135
+2% +$7.32K
ALLO icon
192
Allogene Therapeutics
ALLO
$566M
$378K 0.16%
10,721
+185
+2% +$6.24K
FCT
193
First Trust Senior Floating Rate Income Fund II
FCT
$251M
$372K 0.16%
30,322
+4,457
+17% +$53.1K
PTGX icon
194
Protagonist Therapeutics
PTGX
$8.71B
$372K 0.16%
14,346
+244
+2% +$6.17K
SLRC icon
195
SLR Investment Corp
SLRC
$712M
$371K 0.16%
20,910
+1,137
+6% +$20.8K
NSL
196
DELISTED
NUVEEN SENIOR INCM FD
NSL
$371K 0.16%
66,211
+4,059
+7% +$22.3K
GTHX
197
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$369K 0.16%
15,319
+264
+2% +$6.13K
MTEM
198
DELISTED
Molecular Templates, Inc.
MTEM
$369K 0.16%
1,950
+35
+2% +$6.14K
DSU icon
199
BlackRock Debt Strategies Fund
DSU
$591M
$368K 0.16%
33,423
+3,472
+12% +$37.2K
CDXS icon
200
Codexis
CDXS
$136M
$365K 0.15%
15,949
+290
+2% +$6.78K

Similar funds

Virtus ETF Advisers's Q1 2021 Portfolio in Review

As of Q1 2021, Virtus ETF Advisers held 416 positions worth $237M, down 1.7% from $241M the previous quarter. Its ten largest holdings account for 7.9% of the portfolio.

Virtus ETF Advisers withdrew a net $18.3M in Q1 2021, closing 61 positions and reducing 47 holdings. Its most notable exit was Ryman Hospitality Properties, an estimated $2.57M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 30% of assets, up from 30% a quarter earlier, followed by Real Estate and Energy.

Against the trend, Virtus ETF Advisers opened a new position in Pioneer Natural Resource Co. worth $1.99M.

  • Virtus ETF Advisers's largest Q1 2021 buy was Pioneer Natural Resource Co.: 12,538 shares worth $1.99M.
  • Virtus ETF Advisers added most to Oaktree Specialty Lending in Q1 2021, an estimated $216K increase.
  • Virtus ETF Advisers's biggest Q1 2021 reduction was Avient, cutting an estimated $916K.
  • Virtus ETF Advisers fully exited Ryman Hospitality Properties in Q1 2021, selling an estimated $2.57M.
  • Virtus ETF Advisers's ten largest holdings make up 7.9% of its $237M portfolio in Q1 2021.
  • Virtus ETF Advisers opened 61 new positions and closed 61 in Q1 2021.
  • Virtus ETF Advisers's portfolio value fell 1.7% quarter-over-quarter to $237M.

Based on Virtus ETF Advisers's 13F filing for Q1 2021, filed 17 May 2021.